APN News

  • Tuesday, August, 2020| Today's Market | Current Time: 04:18:23
  • Semler Research Center Invests in New Pharmacological Research and Drug evaluation Facility in Bangalore

    Published on September 29, 2010

    Bangalore: Semler Research Centre Pvt. Ltd. (SRC), a leading contract research organization & subsidiary of  Semler Group,  has announced the inauguration of its 25000 sq ft Centre for Drug evaluation and pharmacology research in Bangalore by Mr. Ronald Semler, Chairman, Semler Group of Companies. The company has invested about $10 million towards its facilities in the last three years and is aiming to double its investment in the next 3 years. In this endeavor the company will increase its headcount to 500 from the existing 150 people in the next 2 years.
    The facility is equipped with three Clinical Pharmacology Units with an 80 bed facility to cater to both early and late phase development as well as life cycle chain management. The company currently has a formulation development center in Bangalore spread across 18,000 sq ft since 2006 and a 48 bed clinical research unit in Salem spread across 18,000 sq ft.
    Speaking on the inauguration, Dr Krathish Bopanna, Executive Director and President, SRC said, “The expansion will give SRC an opportunity to unite the world of pharmaceutical research across the globe and enable us to complete the loop in the drug development cycle by providing easy access to state-of-the-art facilities for early stage research in India. We look forward to added expansion that will contribute towards further evolution of the Indian contract research and development industry. As a company, we also envisage enormous potential in biometric space where we hope to delve further through inorganic growth strategies.”
    Speaking on this milestone of the company, Ronald Semler, Chairman, SRC said, “The parent company Semler Group which has business operations in telecom and defense equipment entered into Pharma services in India because of the thriving generic industry, emerging new drug development capabilities and the impressive IT talent pool available for data management.. India boasts of the highest number of USFDA plants outside the US. Further India is recognized as a hub for CRAMS and clinical trials with dependable quality standards. Bangalore is home to highly skilled people in life science/pharmacy, easy accessibility, global exposure and the most sought after city worldwide, has given us reason to believe in fostering our growth plans here. In this industry, SRC has seen a sharp growth due to our in-house expertise and timely deliveries.”

    Bangalore, Karnataka, India– Semler Research Centre Pvt. Ltd. (SRC), a leading contract research organization & subsidiary of Semler Group, today announced the inauguration of its 25000 sq ft Centre for Drug evaluation and pharmacology research in Bangalore by Mr. Ronald Semler, Chairman, Semler Group of Companies. The company has invested about $10 million towards its facilities in the last three years and is aiming to double its investment in the next 3 years. In this endeavor the company will increase its headcount to 500 from the existing 150 people in the next 2 years.
    The facility is equipped with three Clinical Pharmacology Units with an 80 bed facility to cater to both early and late phase development as well as life cycle chain management. The company currently has a formulation development center in Bangalore spread across 18,000 sq ft since 2006 and a 48 bed clinical research unit in Salem spread across 18,000 sq ft.
    Speaking on the inauguration, Dr Krathish Bopanna, Executive Director and President, SRC said, “The expansion will give SRC an opportunity to unite the world of pharmaceutical research across the globe and enable us to complete the loop in the drug development cycle by providing easy access to state-of-the-art facilities for early stage research in India. We look forward to added expansion that will contribute towards further evolution of the Indian contract research and development industry. As a company, we also envisage enormous potential in biometric space where we hope to delve further through inorganic growth strategies.”
    Speaking on this milestone of the company, Ronald Semler, Chairman, SRC said, “The parent company Semler Group which has business operations in telecom and defense equipment entered into Pharma services in India because of the thriving generic industry, emerging new drug development capabilities and the impressive IT talent pool available for data management.. India boasts of the highest number of USFDA plants outside the US. Further India is recognized as a hub for CRAMS and clinical trials with dependable quality standards. Bangalore is home to highly skilled people in life science/pharmacy, easy accessibility, global exposure and the most sought after city worldwide, has given us reason to believe in fostering our growth plans here. In this industry, SRC has seen a sharp growth due to our in-house expertise and timely deliveries.”

    Loading...